摘要
目的:分析噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的临床效果。方法:选择2014年1月-2015年6月在笔者所在医院就诊的重度支气管哮喘合并COPD患者98例,随机分为对照组和试验组,每组49例,对照组采用复方异丙托溴铵气雾剂,同时给予中等剂量的氟替卡松;试验组加用噻托溴铵干粉气雾剂,并联合大剂量的舒利迭治疗。比较两组治疗效果。结果:两组患者在治疗后1周和4个月后ACT评分均高于治疗前,差异均有统计学意义(P<0.05);但两组患者在治疗后1周、治疗4个月后ACT评分比较,差异无统计学意义(P>0.05)。治疗4个月后,试验组的FEV_1、FEV_1/FVC和FEV1%预计值改善状况均显著的优于对照组,差异均有统计学意义(P<0.05)。治疗4个月后,试验组患者生活质量得分为(90.2±4.7)分,显著高于对照组得分,差异有统计学意义(P<0.05);试验组患者急性加重发作间隔时间为(70.1±5.8)d,显著优于对照组的(43.6±6.9)d,差异有统计学意义(P<0.05);另外,试验组患者急性加重发作次数也显著少于对照组,差异有统计学意义(P<0.05)。结论:利用噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病可以有效的改善患者哮喘情况、提高肺功能和生活质量,在临床中具有推广和应用的价值。
Objective：To analyze the clinical effect of Tiotropium Bromide combined with high-dose Seretide in the treatment of severe bronchial asthma complicated with chronic obstructive pulmonary disease.Method：From January 2014 to June 2015 in our hospital,98 patients with severe bronchial asthma complicated with COPD were randomly divided into control group and experimental group,each group 49 patients.The control group used the compound Ipratropium Bromide aerosol and medium-dose Fluticasone.The experimental group was treated with Tiotropium dry powder aerosol and high-dose Seretide.The treatment effect was compared between the two groups.Result：In both groups,the ACT scores were significantly improved at 1 week and 4 months after treatment,the differences were statistically significant（P〈0.05）.However,in both groups 1 week and 4 months after treatment,there were not statistically significant difference in ACT scores（P〉0.05）.After 4 month of treatment,the FEV1,FEV1/FVC and FEV1% predicated value of the experimental group were better than those of the control group,the differences were statistically significant（P〈0.05）.After 4 month of treatment,the quality of life score in the experimental group was（90.2±4.7） points,significantly higher than that of the control group,the difference was statistically significant（P〈0.05）.The acute exacerbation interval of the experimental group was（70.1±5.8）d,better than（43.6±6.9）d of the control group,the difference was statistically significant（P〈0.05）.The number of acute exacerbations in the experimental group was also significantly lower than that in the control group,the difference was statistically significant（P〈0.05）.Conclusion：The treatment of severe bronchial asthma with chronic obstructive pulmonary disease（COPD） by Tiotropium Bromide combined with high-dose Seretide can effectively improve the asthma and improve the lung function and quality of life.It is worth to be popularized and applied in clinical practice.
出处
《中外医学研究》
2016年第36期8-10,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
噻托溴铵
大剂量舒利迭
重度支气管哮喘
慢性阻塞性肺疾病
Tiotropium Bromide
High-dose Seretide
Severe bronchial asthma
Chronic obstructive pulmonary disease
